Gracell Biotechnologies’ CEO Dr. William Cao Named to Prestigious PharmaVoice 100, Honoring Most Inspiring Life Science Leaders
September 19 2023 - 8:21AM
Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ:
GRCL), a global clinical-stage biopharmaceutical company dedicated
to developing innovative and highly efficacious cell
therapies for the treatment of cancer and autoimmune disease, today
announced that its Founder, Chairman and Chief Executive Officer
William (Wei) Cao, Ph.D., B.M., has been named to the PharmaVoice
100, a recognition of the most inspiring leaders in the
life-sciences industry.
“I am deeply honored and humbled to receive
recognition from our industry’s most prominent leaders,” Dr. Cao
said. “This accolade not only reflects my personal dedication, but
is also an endorsement of the entire Gracell team’s commitment to
developing innovative, next-generation CAR-T cell therapies
designed to address the major challenges that have emerged in this
space, with shorter manufacturing times and potentially improved
T-cell fitness. It's truly inspiring to see the innovation and our
collective efforts acknowledged and celebrated.”
Since 2005, PharmaVoice has been honoring
individuals from across all sectors of the life-sciences industry,
whose leadership reflects a commitment to viewing industry trends
as opportunities, driving innovation, and, ultimately, improving
the lives of patients.
With more than 30 years of experience in the
life science industry, Dr. Cao has led Gracell since its founding
in 2017. Under Dr. Cao's leadership, Gracell has been developing a
rich pipeline of transformational CAR-T therapies, aiming to
broaden the use of breakthrough cell therapies across hematological
malignancies, solid tumors and autoimmune conditions. The lead
candidate, BCMA/CD19 dual-targeting CAR-T GC012F, developed on the
Company’s proprietary, award-winning FasTCAR next-day manufacturing
platform, has demonstrated deep and durable responses in several
investigator-initiated trials (IIT) among patients with multiple
myeloma and B-cell non-Hodgkin's lymphoma. In 2023, Gracell
commenced a Phase 1b/2 clinical trial in U.S. evaluating GC012F for
the treatment of relapsed/refractory multiple myeloma (RRMM) and is
also initiating a company-sponsored Phase 1/2 clinical trial in
China evaluating GC012F in RRMM. Additionally, the Company launched
an IIT evaluating GC012F for the treatment of refractory systemic
lupus erythematosus (rSLE) in the second quarter of this year. In
2022, FasTCAR was named the winner of the Biotech Innovation
category of the 2022 Fierce Life Sciences Innovation Award for its
potential to address major industry obstacles.
PharmaVoice will be recognizing and celebrating
its award honorees on Thursday, Oct. 26 at 3:40-4:30PM EDT. The
PharmaVoice100 honoree program is part of a two-day virtual event
hosted by PharmaVoice and BioPharma Dive’s team of award-winning
journalists – The Next Frontier for the Life Sciences – which will
examine top trends shaping the drug development industry. The event
will bring together newsmaking leaders from across pharma and
biotech for keynote presentations, panels and fireside chats. To
learn more and register for the event, see here.
About Gracell Gracell
Biotechnologies Inc. (“Gracell”) is a global clinical-stage
biopharmaceutical company dedicated to discovering and developing
breakthrough cell therapies for the treatment of cancers and
autoimmune diseases. Leveraging its innovative FasTCAR and TruUCAR
technology platforms and SMART CAR™ technology module, Gracell is
developing a rich clinical-stage pipeline of multiple autologous
and allogeneic product candidates with the potential to overcome
major industry challenges that persist with conventional CAR-T
therapies, including lengthy manufacturing time, suboptimal cell
quality, high therapy cost, and lack of effective CAR-T therapies
for solid tumors and autoimmune diseases. The lead candidate
BCMA/CD19 dual-targeting FasTCAR-T GC012F is currently being
evaluated in clinical studies for the treatment of multiple
myeloma, B-NHL and systemic lupus erythematosus (SLE). For more
information on Gracell, please visit
www.gracellbio.com. Follow @GracellBio on LinkedIn.
Cautionary Noted Regarding
Forward-Looking StatementsStatements in this press release
about future expectations, plans, and prospects, as well as any
other statements regarding matters that are not historical facts,
may constitute “forward-looking statements” within the meaning of
The Private Securities Litigation Reform Act of 1995. The words
“anticipate,” “look forward to,” “believe,” “continue,” “could,”
“estimate,” “expect,” “intend,” “may,” “plan,” “potential,”
“predict,” “project,” “should,” “target,” “will,” “would” and
similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words. Actual results may differ materially from
those indicated by such forward-looking statements as a result of
various important factors, including factors discussed in the
section entitled “Risk Factors” in Gracell’s most recent annual
report on Form 20-F, as well as discussions of potential risks,
uncertainties, and other important factors in Gracell’s subsequent
filings with the U.S. Securities and Exchange Commission. Any
forward-looking statements contained in this press release speak
only as of the date hereof. Gracell specifically disclaims any
obligation to update any forward-looking statement, whether due to
new information, future events, or otherwise. Readers should not
rely upon the information on this page as current or accurate after
its publication date.
Media contactsMarvin
Tangmarvin.tang@gracellbio.com
Jessica Laubjessica.laub@westwicke.com
Investor contactsGracie
Tonggracie.tong@gracellbio.com
Stephanie
Carringtonstephanie.carrington@westwicke.com
Gracell Biotechnologies (NASDAQ:GRCL)
Historical Stock Chart
From May 2024 to Jun 2024
Gracell Biotechnologies (NASDAQ:GRCL)
Historical Stock Chart
From Jun 2023 to Jun 2024